Immunocore, Eli Lilly deal

Immunocore partnered with Lilly to study combination regimens including Immunocore’s IMCgp100 and Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) to treat melanoma. The companies will conduct a Phase Ib/II trial of IMCgp100 plus galunisertib to treat metastatic cutaneous melanoma and a Phase Ib/II trial of IMCgp100 plus merestinib to treat metastatic uveal melanoma. Lilly will sponsor the trials, which are expected to begin next year. ...